Fredun Pharmaceuticals Intrinsic Value

Fredun Pharmaceuticals intrinsic value. Fredun Pharmaceuticals (FREDUN) median intrinsic value is ₹926.67 from 9 valuation models (range ₹512–₹3416), vs current price ₹1708.00 — -45.7% downside (Trading Above Calculated Value), margin of safety -84.3%. Browse Fredun Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹1708.00
Primary Intrinsic Value
₹967.12
Market Cap
₹1025 Cr
-45.7% Downside
Median Value
₹926.67
Value Range
₹512 - ₹3416
Assessment
Trading Above Calculated Value
Safety Margin
-84.3%

FREDUN Valuation Methods Summary — DCF, Graham Number & P/E

Fredun Pharmaceuticals intrinsic value across 9 models vs current price ₹1708.00 — upside/downside and value range per method. For current market price and key ratios, visit FREDUN share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹967.12 ₹773.70 - ₹1160.54 -43.4% EPS: ₹43.96, Sector P/E: 22x
Book Value Method asset ₹926.67 ₹834.00 - ₹1019.34 -45.7% Book Value/Share: ₹463.33, P/B: 2.0x
Revenue Multiple Method revenue ₹3416.00 ₹3074.40 - ₹3757.60 +100.0% Revenue/Share: ₹1773.33, P/S: 2.0x
EBITDA Multiple Method earnings ₹2733.33 ₹2460.00 - ₹3006.66 +60.0% EBITDA: ₹164.00Cr, EV/EBITDA: 10x
PEG Ratio Method growth ₹512.40 ₹461.16 - ₹563.64 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹679.18 ₹611.26 - ₹747.10 -60.2% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹2026.67 ₹1824.00 - ₹2229.34 +18.7% ROE: 27.3%, P/E Multiple: 16x
Graham Defensive Method conservative ₹676.97 ₹609.27 - ₹744.67 -60.4% EPS: ₹43.96, BVPS: ₹463.33
Dividend Yield Method dividend ₹512.40 ₹461.16 - ₹563.64 -70.0% DPS: ₹0.70, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

FREDUN Intrinsic Value vs Market Price — All Valuation Models

Fredun Pharmaceuticals fair value range ₹512–₹3416 vs current market price ₹1708.00 across 9 valuation models. Analyse Fredun Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.

FREDUN Intrinsic Value Analysis — Undervalued or Overvalued?

Fredun Pharmaceuticals median intrinsic value ₹926.67, current price ₹1708.00 — Trading Above Calculated Value by 45.7%, margin of safety -84.3%.

What is the intrinsic value of FREDUN?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Fredun Pharmaceuticals (FREDUN) is ₹926.67 (median value). With the current market price of ₹1708.00, this represents a -45.7% variance from our estimated fair value.

The valuation range spans from ₹512.40 to ₹3416.00, indicating ₹512.40 - ₹3416.00.

Is FREDUN undervalued or overvalued?

Based on our multi-method analysis, Fredun Pharmaceuticals (FREDUN) appears to be trading above calculated value by approximately 45.7%.

FREDUN Financial Health — Key Ratios vs Industry Benchmarks

Fredun Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 27.3% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 15.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 1.66x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

FREDUN Cash Flow Quality — Operating & Free Cash Flow

Fredun Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹12 Cr ₹-25 Cr Positive Operating Cash Flow 6/10
March 2025 ₹-17 Cr ₹-20 Cr Negative Cash Flow 3/10